Gallant Secures FDA Pathway and Reports Positive Data for IV Stem-Cell Therapy in Canine Osteoarthritis

New updates have been reported about Gallant.

Gallant has gained eligibility from the U.S. FDA Center for Veterinary Medicine to use the expanded conditional approval pathway for its off-the-shelf uterine-derived mesenchymal stromal cell therapy targeting canine osteoarthritis, with conditional approval targeted for 2028. In parallel, the company reported positive topline results from a randomized, blinded, placebo-controlled pilot study of intravenous dosing in 88 client-owned dogs with naturally occurring osteoarthritis.

Dogs receiving Gallant’s stem-cell therapy showed statistically significant improvements versus placebo in validated owner-reported outcomes at Days 60 and 90, with veterinarian and pet parent assessments of mobility, pain, and quality of life consistently favoring the treated group. No treatment-related serious adverse events were observed, supporting the safety of repeated intravenous administration of donor-derived cells.

Gallant’s strategy centers on IV delivery rather than intra-articular injection, potentially lowering procedural complexity by avoiding sedation, anesthesia, and specialist referral, and thereby broadening access across general veterinary practices. The company positions its MSC therapy as targeting systemic and local immune dysregulation that drives osteoarthritis, aiming not only to manage clinical signs but also to modify disease progression.

FDA-CVM has granted expanded conditional approval eligibility for both Gallant’s canine and feline osteoarthritis programs, which could accelerate time to market in a large and under-served segment where osteoarthritis affects a substantial portion of aging dogs. Management views these regulatory and clinical milestones as a key step toward creating a new category of veterinary regenerative care and building a commercial franchise in chronic musculoskeletal disease.

Gallant is also investing in professional education through its GallantU continuing-education platform, which offers RACE-approved content on regenerative medicine and canine osteoarthritis to drive future adoption. The company’s osteoarthritis therapy remains an investigational new animal drug pending further regulatory review and must progress through additional clinical work and FDA evaluation before commercialization.